Gsa Capital Partners LLP Seagen Inc. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $1.38 Million - $1.52 Million	7,369 New	7,369 $1.42 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $187,619 - $249,812	1,387 Added 56.13%	3,858 $528,000
Q2 2022 Aug 09, 2022	BUY	$108.81 - $179.33 $268,869 - $443,124	2,471 New	2,471 $437,000
Q1 2022 May 11, 2022	SELL	$119.61 - $157.85 $320,315 - $422,722	-2,678 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $381,802 - $511,123	2,678 New	2,678 $414,000

Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $283,902 - $338,451	-1,993 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$135.08 - $161.1 $269,214 - $321,072	1,993 New	1,993 $315,000
Q1 2021 May 10, 2021	SELL	$137.51 - $190.8 $420,093 - $582,894	-3,055 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$164.63 - $211.93 $502,944 - $647,446	3,055 New	3,055 $535,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.